Sharps Technology Inc. (STSS): Nasdaq/NYSE listing notice — Sharps Tech gets Nasdaq delisting notice for bid price non-compliance; will appeal

Sharps Technology Inc.

Notified on March 12, 2025 for failing to maintain minimum $1.00 bid price for 30 consecutive days.
Prior 1-for-22 reverse split within past year makes company ineligible for standard 180-day cure period.
Company plans to timely file a hearing request with Nasdaq Hearings Panel, which automatically stays delisting.
No assurance of regaining compliance; securities (STSS, STSSW) remain listed pending panel decision.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Sharps Technology Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)(iv)

Exact text from the filing

March 12, 2025, Sharps Technology, Inc. (the “ Company ”), was notified by the staff (the “ Staff ”) of The Nasdaq Stock Market, LLC (“ Nasdaq ”) that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market as the bid price of its securities had closed at less than $1.00 per share over the previous 30 consecutive business days. Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the rule. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), th

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Sharps Technology Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-010375

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.